+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

House Dust Mite Allergy - Pipeline Review, H2 2020

  • ID: 5137263
  • Drug Pipelines
  • July 2020
  • Region: Global
  • 61 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Advagene Biopharma Co Ltd
  • ALK-Abello AS
  • Allergy Therapeutics Plc
  • Anergis SA
  • Biomay AG
  • Genetic Immunity Inc
  • MORE
House Dust Mite Allergy - Pipeline Review, H2 2020

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide House Dust Mite Allergy - Pipeline Review, H2 2020, provides an overview of the House Dust Mite Allergy (Immunology) pipeline landscape.

House dust mite allergy is an allergic reaction to tiny bugs that commonly live in house dust. Symptoms include frequent sneezing, a runny, stuffy, itchy nose and irritated eyes. Asthma and eczema can also be triggered by a dust mite allergy. Symptoms often worsen when the individual comes in close proximity to disturbed dust. The predisposing factors include family history and age. Treatment includes antihistamines, decongestants and corticosteroids.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide House Dust Mite Allergy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for House Dust Mite Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The House Dust Mite Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

House Dust Mite Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for House Dust Mite Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in House Dust Mite Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates House Dust Mite Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for House Dust Mite Allergy (Immunology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for House Dust Mite Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding House Dust Mite Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Advagene Biopharma Co Ltd
  • ALK-Abello AS
  • Allergy Therapeutics Plc
  • Anergis SA
  • Biomay AG
  • Genetic Immunity Inc
  • MORE
  • Introduction
  • Report Coverage
  • House Dust Mite Allergy - Overview
  • House Dust Mite Allergy - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • House Dust Mite Allergy - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • House Dust Mite Allergy - Companies Involved in Therapeutics Development
  • Advagene Biopharma Co Ltd
  • ALK-Abello AS
  • Allergy Therapeutics Plc
  • Anergis SA
  • Biomay AG
  • Genetic Immunity Inc
  • Polyrizon Ltd
  • Roxall Medizin GmbH
  • Stallergenes Greer Ltd
  • Zhejiang I-Biological Technology Co Ltd
  • House Dust Mite Allergy - Drug Profiles
  • AD-17002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Allergan for Dust Mite Allergy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AM-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BM-35 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • House Dust Mite Allergy - Dormant Projects
  • House Dust Mite Allergy - Discontinued Products
  • House Dust Mite Allergy - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
List of Tables
  • Number of Products under Development for House Dust Mite Allergy, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • House Dust Mite Allergy - Pipeline by Advagene Biopharma Co Ltd, H2 2020
  • House Dust Mite Allergy - Pipeline by ALK-Abello AS, H2 2020
  • House Dust Mite Allergy - Pipeline by Allergy Therapeutics Plc, H2 2020
  • House Dust Mite Allergy - Pipeline by Anergis SA, H2 2020
  • House Dust Mite Allergy - Pipeline by Biomay AG, H2 2020
  • House Dust Mite Allergy - Pipeline by Genetic Immunity Inc, H2 2020
  • House Dust Mite Allergy - Pipeline by Polyrizon Ltd, H2 2020
  • House Dust Mite Allergy - Pipeline by Roxall Medizin GmbH, H2 2020
  • House Dust Mite Allergy - Pipeline by Stallergenes Greer Ltd, H2 2020
  • House Dust Mite Allergy - Pipeline by Zhejiang I-Biological Technology Co Ltd, H2 2020
  • House Dust Mite Allergy - Dormant Projects, H2 2020
  • House Dust Mite Allergy - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for House Dust Mite Allergy, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
3 of 3
  • Advagene Biopharma Co Ltd
  • ALK-Abello AS
  • Allergy Therapeutics Plc
  • Anergis SA
  • Biomay AG
  • Genetic Immunity Inc
  • Polyrizon Ltd
  • Roxall Medizin GmbH
  • Stallergenes Greer Ltd
  • Zhejiang I-Biological Technology Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll